



Supplementary Figure S1. Targeted therapeutics vemurafenib (VEM) and trametinib (TRA) reduce the frequency of Ki-67- and MITF-positive melanoma cells in a cell line- and oxygen-dependent manner. Representative dot plots of melanoma cells stained with anti-MITF (A) and anti-Ki-67 (B) antibodies after 24 h and 48 h of treatment with either 50nM TRA or 10 μ M VEM. Cells positive for each marker are labeled in yellow.